Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03268174 · ClinicalTrials.gov registry record · NA
Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.
A NA study of Atopic Dermatitis Eczema, sponsored by AOBiome.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03268174: Completed NA study of Atopic Dermatitis Eczema, sponsored by AOBiome.
NCT03268174 is a NA study of Atopic Dermatitis Eczema that has completed, run by AOBiome. The registered enrollment target is 19 participants, below the 199-participant average among 8 other Atopic Dermatitis Eczema trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03268174, a NA study of Atopic Dermatitis Eczema, has completed, sponsored by AOBiome.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to observe the performance of a cosmetic product, AO+Mist, on the appearance of arm skin in subjects with atopic dermatitis
Conditions Studied
Interventions
- OTHER Placebo
- OTHER AO+Mist
Study Locations (1)
Illinois
- Medical Dermatology Associates of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2017-02-13 |
| Phase | NA |
What the finished NCT03268174 record still lists
NCT03268174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 199-participant average among 8 other Atopic Dermatitis Eczema trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Atopic Dermatitis Eczema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03268174 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03268174 about?
NCT03268174 is a clinical study titled "Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.". The purpose of this study is to observe the performance of a cosmetic product, AO+Mist, on the appearance of arm skin in subjects with atopic dermatitis
What is the current status of trial NCT03268174?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2016-05-11. Estimated completion is 2017-02-13.
What conditions does trial NCT03268174 study?
This clinical trial studies the following conditions: Atopic Dermatitis Eczema.
What interventions are being tested in trial NCT03268174?
The interventions under investigation include: Placebo (OTHER), AO+Mist (OTHER).
Who is sponsoring clinical trial NCT03268174?
This trial is sponsored by AOBiome, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03268174 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03268174's enrollment target sits among peer trials
19 8th of 8 higher than 1 of 8 other Atopic Dermatitis Eczema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis Eczema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
COMPLETED · NA
-
Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema
COMPLETED · NA
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
RECRUITING · Phase 2
-
Seal, Stopping Eczema and Allergy Study
ACTIVE NOT RECRUITING · Phase 2
-
Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI